Aratana Therapeutics Inc. to Report Second Quarter Financial Results
Conference Call and Webcast scheduled for Tuesday August 12, 2014, 8:30 a.m. ET
KANSAS CITY, Kan., Aug. 7, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals will host a conference call and live audio webcast on Tuesday, August 12, 2014, at 8:30 a.m. ET, to discuss its financial results for the quarter ended June 30, 2014.
Conference Call Information:
Interested participants and investors may access the conference call by dialing:
- 1 (877) 870-4263 (U.S./Canada)
- 1 (412) 317-0790 (international)
A replay of the call will be available for 90 days beginning at approximately 10:30 a.m. ET on August 12, 2014. Access numbers for this replay are:
- 1 (877) 344-7529 (U.S./Canada)
- 1 (412) 317-0088 (international)
- Conference ID: 10050934
An audio webcast will be accessible via the Investors section of the Aratana Therapeutics website aratana.investorroom.com and will remain available for 90 days.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes more than fifteen therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
For Investor Inquiries:
Chief Financial Officer
For Media Inquiries:
Tiberend Strategic Advisors, Inc.
SOURCE Aratana Therapeutics, Inc.